Literature DB >> 24552249

Hypoallergenic derivatives of Fel d 1 obtained by rational reassembly for allergy vaccination and tolerance induction.

M Curin1, M Weber, T Thalhamer, I Swoboda, M Focke-Tejkl, K Blatt, P Valent, K Marth, T Garmatiuk, H Grönlund, J Thalhamer, S Spitzauer, R Valenta.   

Abstract

BACKGROUND AND
OBJECTIVE: The major cat allergen Fel d 1 represents one of the most important respiratory allergens. Aim of this study was to engineer recombinant Fel d 1 derivatives with reduced IgE reactivity and preserved T cell epitopes for vaccination and tolerance induction.
METHODS: Seven recombinant mosaic proteins were generated by reassembly of non-IgE-reactive peptides of Fel d 1 which contained the sequence elements for induction of allergen-specific blocking IgG antibodies and T cell epitopes. Mosaic proteins were expressed in Escherichia coli using codon-optimized synthetic genes and compared with Fel d 1 regarding structural fold by circular dichroism, IgE-binding capacity, activation of allergic patients' basophils and ability to induce allergen-specific blocking IgG antibodies upon immunization.
RESULTS: Although each of the mosaic proteins had lost the alpha-helical fold typical for Fel d 1, a strong reduction in IgE reactivity as well as allergenic activity in basophil activation assays was only obtained for three constructs, two reassembled fragments (Fel d 1 MB, Fel d 1 MC) and a fusion of the latter two (Fel d 1 MF) in which the cysteines of Fel d 1 MC were replaced by serines. Immunization of rabbits with Fel d 1 MB, MC and MF induced high levels of IgG antibodies that inhibited IgE reactivity of cat-allergic patients to Fel d 1 in a comparable manner as IgG induced with the wild-type allergen.
CONCLUSIONS: We report the development of hypoallergenic reassembled Fel d 1 proteins suitable for vaccination and tolerance induction in cat-allergic patients.
© 2014 John Wiley & Sons Ltd.

Entities:  

Keywords:  Fel d 1; allergen-specific immunotherapy; cat allergy; hypoallergenic vaccine; recombinant allergen; tolerance induction; vaccination

Mesh:

Substances:

Year:  2014        PMID: 24552249      PMCID: PMC4678659          DOI: 10.1111/cea.12294

Source DB:  PubMed          Journal:  Clin Exp Allergy        ISSN: 0954-7894            Impact factor:   5.018


  45 in total

Review 1.  Immunological mechanisms of allergen-specific immunotherapy.

Authors:  Mark Larché; Cezmi A Akdis; Rudolf Valenta
Journal:  Nat Rev Immunol       Date:  2006-10       Impact factor: 53.106

2.  Development of a functional in vitro assay as a novel tool for the standardization of allergen extracts in the human system.

Authors:  L Vogel; D Lüttkopf; L Hatahet; D Haustein; S Vieths
Journal:  Allergy       Date:  2005-08       Impact factor: 13.146

3.  Rational design of hypoallergens applied to the major cat allergen Fel d 1.

Authors:  T Saarne; L Kaiser; H Grönlund; O Rasool; G Gafvelin; M van Hage-Hamsten
Journal:  Clin Exp Allergy       Date:  2005-05       Impact factor: 5.018

4.  IgE epitopes on the cat (Felis domesticus) major allergen Fel d I: a study with overlapping synthetic peptides.

Authors:  F J van Milligen; W van 't Hof; M van den Berg; R C Aalberse
Journal:  J Allergy Clin Immunol       Date:  1994-01       Impact factor: 10.793

5.  The crystal structure of the major cat allergen Fel d 1, a member of the secretoglobin family.

Authors:  Liselotte Kaiser; Hans Grönlund; Tatyana Sandalova; Hans-Gustaf Ljunggren; Marianne van Hage-Hamsten; Adnane Achour; Gunter Schneider
Journal:  J Biol Chem       Date:  2003-07-08       Impact factor: 5.157

6.  A hypoallergenic vaccine obtained by tail-to-head restructuring of timothy grass pollen profilin, Phl p 12, for the treatment of cross-sensitization to profilin.

Authors:  Kerstin Westritschnig; Birgit Linhart; Margarete Focke-Tejkl; Tea Pavkov; Walter Keller; Tanja Ball; Adriano Mari; Arnulf Hartl; Angelika Stöcklinger; Sandra Scheiblhofer; Josef Thalhamer; Fatima Ferreira; Stefan Vieths; Lothar Vogel; Alexandra Böhm; Peter Valent; Rudolf Valenta
Journal:  J Immunol       Date:  2007-12-01       Impact factor: 5.422

Review 7.  The major cat allergen, Fel d 1, in diagnosis and therapy.

Authors:  Hans Grönlund; Tiiu Saarne; Guro Gafvelin; Marianne van Hage
Journal:  Int Arch Allergy Immunol       Date:  2009-10-22       Impact factor: 2.749

8.  Amino acid sequence of Fel dI, the major allergen of the domestic cat: protein sequence analysis and cDNA cloning.

Authors:  J P Morgenstern; I J Griffith; A W Brauer; B L Rogers; J F Bond; M D Chapman; M C Kuo
Journal:  Proc Natl Acad Sci U S A       Date:  1991-11-01       Impact factor: 11.205

9.  Effect of T-cell peptides derived from Fel d 1 on allergic reactions and cytokine production in patients sensitive to cats: a randomised controlled trial.

Authors:  W L G Oldfield; M Larché; A B Kay
Journal:  Lancet       Date:  2002-07-06       Impact factor: 79.321

Review 10.  Vaccines for allergy.

Authors:  Birgit Linhart; Rudolf Valenta
Journal:  Curr Opin Immunol       Date:  2012-04-20       Impact factor: 7.486

View more
  16 in total

Review 1.  Recombinant Allergens in Structural Biology, Diagnosis, and Immunotherapy.

Authors:  Angelika Tscheppe; Heimo Breiteneder
Journal:  Int Arch Allergy Immunol       Date:  2017-05-04       Impact factor: 2.749

Review 2.  Modified Allergens for Immunotherapy.

Authors:  Pattraporn Satitsuksanoa; Anna Głobińska; Kirstin Jansen; Willem van de Veen; Mübeccel Akdis
Journal:  Curr Allergy Asthma Rep       Date:  2018-02-16       Impact factor: 4.806

Review 3.  Facing Hymenoptera Venom Allergy: From Natural to Recombinant Allergens.

Authors:  Amilcar Perez-Riverol; Débora Lais Justo-Jacomini; Ricardo de Lima Zollner; Márcia Regina Brochetto-Braga
Journal:  Toxins (Basel)       Date:  2015-07-09       Impact factor: 4.546

4.  Clustering of conformational IgE epitopes on the major dog allergen Can f 1.

Authors:  Mirela Curin; Milena Weber; Gerhard Hofer; Danijela Apostolovic; Walter Keller; Renate Reininger; Ines Swoboda; Susanne Spitzauer; Margit Focke-Tejkl; Marianne van Hage; Rudolf Valenta
Journal:  Sci Rep       Date:  2017-09-22       Impact factor: 4.379

5.  Hypoallergenic Variant of the Major Egg White Allergen Gal d 1 Produced by Disruption of Cysteine Bridges.

Authors:  Pathum Dhanapala; Dulashi Withanage-Dona; Mimi L K Tang; Tim Doran; Cenk Suphioglu
Journal:  Nutrients       Date:  2017-02-21       Impact factor: 5.717

Review 6.  The Evolution of Human Basophil Biology from Neglect towards Understanding of Their Immune Functions.

Authors:  Markus Steiner; Sara Huber; Andrea Harrer; Martin Himly
Journal:  Biomed Res Int       Date:  2016-12-19       Impact factor: 3.411

7.  Treating cat allergy with monoclonal IgG antibodies that bind allergen and prevent IgE engagement.

Authors:  J M Orengo; A R Radin; V Kamat; A Badithe; L H Ben; B L Bennett; S Zhong; D Birchard; A Limnander; A Rafique; J Bautista; A Kostic; D Newell; X Duan; M C Franklin; W Olson; T Huang; N A Gandhi; L Lipsich; N Stahl; N J Papadopoulos; A J Murphy; G D Yancopoulos
Journal:  Nat Commun       Date:  2018-04-12       Impact factor: 14.919

Review 8.  Important and specific role for basophils in acute allergic reactions.

Authors:  P Korošec; B F Gibbs; M Rijavec; A Custovic; P J Turner
Journal:  Clin Exp Allergy       Date:  2018-03-23       Impact factor: 5.018

Review 9.  Next-Generation of Allergen-Specific Immunotherapies: Molecular Approaches.

Authors:  Mirela Curin; Musa Khaitov; Alexander Karaulov; Leyla Namazova-Baranova; Raffaela Campana; Victoria Garib; Rudolf Valenta
Journal:  Curr Allergy Asthma Rep       Date:  2018-06-09       Impact factor: 4.806

Review 10.  An update on molecular cat allergens: Fel d 1 and what else? Chapter 1: Fel d 1, the major cat allergen.

Authors:  B Bonnet; K Messaoudi; F Jacomet; E Michaud; J L Fauquert; D Caillaud; B Evrard
Journal:  Allergy Asthma Clin Immunol       Date:  2018-04-10       Impact factor: 3.406

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.